Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2017.09.012
Abstract: Background The use of the potent oral P2Y12 inhibitors prasugrel and ticagrelor in patients with acute coronary syndromes (ACS) has a favorable net clinical effect compared with clopidogrel and is recommended as first‐line therapy. However,… read more here.
Keywords: p2y12; safety; efficacy; nonelderly patients ... See more keywords
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Sign Up to like & getrecommendations! Published in 2022 at "Stroke and Vascular Neurology"
DOI: 10.1136/svn-2021-001294
Abstract: Background Stroke after acute coronary syndrome (ACS) can be devastating. It is uncertain whether the risks of ischaemic stroke or intracranial haemorrhage (ICH) are associated with different choices of P2Y12 inhibitors (potent P2Y12 inhibitors such… read more here.
Keywords: potent p2y12; ischaemic stroke; clopidogrel; risk ... See more keywords
Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.
Sign Up to like & getrecommendations! Published in 2022 at "Reviews in cardiovascular medicine"
DOI: 10.31083/j.rcm2303081
Abstract: BACKGROUND Superiority of potent P2Y12 inhibitors over clopidogrel after an acute coronary syndrome (ACS) has been well established, however potent P2Y12 inhibition is responsible for more adverse events, which may influence patient adherence to treatment.… read more here.
Keywords: adherence; potent p2y12; potent; therapy ... See more keywords
Unguided De-Escalation Strategy From Potent P2Y12 Inhibitors in Patients Presented With ACS: When, Whom and How?
Sign Up to like & getrecommendations! Published in 2022 at "Korean Circulation Journal"
DOI: 10.4070/kcj.2022.0022
Abstract: https://e-kcj.org In patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is an essential strategy of their management. According to the current guidelines, it is generally recommended to… read more here.
Keywords: unguided escalation; strategy; escalation strategy; potent p2y12 ... See more keywords